Michael Burkes Brophy has filed a Form 144 to sell 313 shares of common stock in Natera, Inc., valued at approximately $129,675. This filing, submitted on November 2, 2026, is significant as it follows a series of transactions involving the sale of shares by Brophy, indicating ongoing activity in the market.

Natera, Inc. operates in the medical laboratory services industry and is known for its advanced genetic testing and diagnostics. The company is incorporated in Delaware and has its headquarters in Austin, Texas. As of the recent filings, Natera is listed under the SEC file number 001-37478.

The filing states that Brophy acquired the shares through restricted stock units that vested on October 31, 2026. The notice included details of previous sales, showing that Brophy sold 1,906 shares on October 30, 2026, for gross proceeds of approximately $811,098.3, and additional sales on October 28 and 27, 2026, totaling over $800,000.

This development may affect various stakeholders, including Natera’s investors and competitors in the medical laboratory services market. The recent activity raises questions about insider trading and the timing of stock sales, which could lead to increased scrutiny within the industry.

The filing does not specify what actions will follow this sale, leaving investors and analysts to speculate on the implications of Brophy's ongoing stock transactions.